1. Wendt, A., Adhoute, X., Castellani, P., Oules, V., Ansaldi, C., Benali, S., et al. (2014). Chronic hepatitis C: future treatment. Clin Pharm, 6 (eCollection), 1–17.
2. Shepard, C., Finelli, L., & Alter, M. (2005). Global epidemiology of hepatitis C virus infection. Lancet ID, 5(9), 558–567.
3. National Institute for Clinical Excellence (2004). Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. http://www.nice.org.uk/nicemedia/live/11524/32809/32809.pdf , accessed May 10, 2014.
4. Ly, K., Xing, J., Klevens, M., Jiles, R., Ward, J., & Holmberg, S. (2012). The growing burden of mortality from viral hepatitis in the US, 1999–2007. Annals of Internal Medicine, 156, 271–278.
5. Keeling, M., & Eames, K. (2005). Networks and epidemic models. Journal of the Royal Society, Interface, 2(4), 295–307.